Literature DB >> 19772040

Interstitial pneumonitis in the transplant patient: consider sirolimus-associated pulmonary toxicity.

Jacob Feagans1, David Victor, Martin Moehlen, Sander S Florman, Fredric Regenstein, Luis A Balart, Shobha Joshi, Mary T Killackey, Douglas P Slakey, Anil S Paramesh.   

Abstract

Interstitial pneumonia in a transplant patient can have a varied etiology. Sirolimus (Rapamycin; Rapamune) is a popularly used immunosuppressant in solid organ transplantation that has anecdotally been associated with pulmonary toxicity. Sirolimus-induced pulmonary toxicity consists of a range of syndromes that is characterized by the presence of organizing pneumonia, interstitial pneumonitis, pulmonary alveolar proteinosis, focal fibrosis, or by the presence of alveolar hemorrhage. Diagnosis can be challenging and is usually made by exclusion of other etiologies. In this report we present two cases of sirolimus-associated pulmonary toxicity with a review of the literature.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19772040

Source DB:  PubMed          Journal:  J La State Med Soc        ISSN: 0024-6921


  8 in total

1.  The Akt inhibitor, triciribine, ameliorates chronic hypoxia-induced vascular pruning and TGFβ-induced pulmonary fibrosis.

Authors:  Maha Abdalla; Harika Sabbineni; Roshini Prakash; Adviye Ergul; Susan C Fagan; Payaningal R Somanath
Journal:  Br J Pharmacol       Date:  2015-07-06       Impact factor: 8.739

2.  Interstitial pneumonitis is a frequent complication in liver transplant recipients treated with sirolimus.

Authors:  A Morcos; S Nair; M P Keane; N G McElvaney; P A McCormick
Journal:  Ir J Med Sci       Date:  2012-01-15       Impact factor: 1.568

Review 3.  Emerging Perspectives on mTOR Inhibitor-Associated Pneumonitis in Breast Cancer.

Authors:  Ricardo H Alvarez; Rabih I Bechara; Michael J Naughton; Javier A Adachi; James M Reuben
Journal:  Oncologist       Date:  2018-02-27

4.  Rapamycin Regulates Bleomycin-Induced Lung Damage in SP-C-Deficient Mice.

Authors:  Satish K Madala; Melissa D Maxfield; Cynthia R Davidson; Stephanie M Schmidt; Daniel Garry; Machiko Ikegami; William D Hardie; Stephan W Glasser
Journal:  Pulm Med       Date:  2011-03-21

5.  Pulmonary alveolar proteinosis due to mycophenolate and cyclosporine combination therapy in a renal transplant recipient.

Authors:  Ashfaq Hasan; Raja Ram; Tln Swamy
Journal:  Lung India       Date:  2014-07

Review 6.  Interstitial Lung Disease Associated with mTOR Inhibitors in Solid Organ Transplant Recipients: Results from a Large Phase III Clinical Trial Program of Everolimus and Review of the Literature.

Authors:  Patricia Lopez; Sven Kohler; Seema Dimri
Journal:  J Transplant       Date:  2014-12-18

7.  In Vitro Identification of New Transcriptomic and miRNomic Profiles Associated with Pulmonary Fibrosis Induced by High Doses Everolimus: Looking for New Pathogenetic Markers and Therapeutic Targets.

Authors:  Simona Granata; Gloria Santoro; Valentina Masola; Paola Tomei; Fabio Sallustio; Paola Pontrelli; Matteo Accetturo; Nadia Antonucci; Pierluigi Carratù; Antonio Lupo; Gianluigi Zaza
Journal:  Int J Mol Sci       Date:  2018-04-20       Impact factor: 5.923

8.  Sirolimus-induced secondary pulmonary alveolar proteinosis.

Authors:  Stephanie Wang; Elinor Lee; Ryan Lau; Tisha Wang
Journal:  Respir Med Case Rep       Date:  2021-12-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.